Home › Funds › Merck & Co., Inc. › KYMR
Merck & Co., Inc. position in KYMR
KYMERA THERAPEUTICS INC · Health Care
Merck & Co., Inc. reported holding 772,165 shares of KYMR (KYMERA THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$86.3M, representing 10.52% of its reported portfolio and ranking #3 among its reported holdings. Merck & Co., Inc. has disclosed KYMR holdings in 8 of the last 8 reported quarters, going back to Q4 2024.
Last updated: 2026-11-14 · Source: SEC EDGAR Form 13F-HR
How Merck & Co., Inc.'s KYMR position evolved
Merck & Co., Inc. first disclosed a stake in KYMR in Q4 2024 at 772,165 shares (US$31.1M). The position peaked in Q2 2026 at 772,165 shares, worth US$88.5M. Across 8 filings, Merck & Co., Inc. held the position steady without any share-count change. The most recent filing (Q3 2026) shows 772,165 shares valued at US$86.3M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2024 | 772.16K | $31.06M | New |
| Q1 2025 | 772.16K | $21.13M | Hold |
| Q2 2025 | 772.16K | $33.70M | Hold |
| Q3 2025 | 772.16K | $43.70M | Hold |
| Q4 2025 | 772.16K | $60.08M | Hold |
| Q1 2026 | 772.16K | $64.31M | Hold |
| Q2 2026 | 772.16K | $88.54M | Hold |
| Q3 2026 | 772.16K | $86.32M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About KYMR and 13F data
KYMR (KYMERA THERAPEUTICS INC) is a Health Care company. 54 other funds we track also report a position in KYMR — the largest reported positions include BAKER BROS. ADVISORS LP (US$992.7M), Avoro Capital Advisors LLC (US$857.1M), T. Rowe Price Investment Management, Inc. (US$717.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding KYMR
- BAKER BROS. ADVISORS LP 8.66M sh · $992.73M · Q2 2026
- Avoro Capital Advisors LLC 7.47M sh · $857.13M · Q2 2026
- T. Rowe Price Investment Management, Inc. 6.26M sh · $717.52M · Q2 2026
- BVF INC/IL 3.87M sh · $444.01M · Q2 2026
- Atlas Venture Life Science Advisors, LLC 2.85M sh · $318.33M · Q3 2026
- Siren, L.L.C. 2.78M sh · $311.32M · Q3 2026
- DRIEHAUS CAPITAL MANAGEMENT LLC 919.23K sh · $105.41M · Q2 2026
- FRONTIER CAPITAL MANAGEMENT CO LLC 740.87K sh · $84.96M · Q2 2026
- EVENTIDE ASSET MANAGEMENT, LLC 490.61K sh · $54.84M · Q3 2026
- Rock Springs Capital Management LP 453.16K sh · $51.96M · Q2 2026
- Boxer Capital Management, LLC 429.10K sh · $49.20M · Q2 2026
- BRAIDWELL LP 378.16K sh · $43.36M · Q2 2026
More on Merck & Co., Inc.
FAQ
How long has Merck & Co., Inc. held KYMR?
Merck & Co., Inc. has disclosed KYMR holdings in 8 of the last 8 reported quarters, going back to Q4 2024.
What is Merck & Co., Inc.'s current position in KYMR?
As of Q3 2026, Merck & Co., Inc. holds 772.16K shares of KYMR (KYMERA THERAPEUTICS INC), valued at $86.32M, representing 10.52% of its reported portfolio and ranking #3.
Has Merck & Co., Inc. been buying or selling KYMR?
In the latest 13F filing (Q3 2026), Merck & Co., Inc. held unchanged its position in KYMR. The position peaked in Q2 2026 at 772.16K shares.
Which other funds hold KYMR?
Other major institutional holders of KYMR include BAKER BROS. ADVISORS LP, Avoro Capital Advisors LLC, T. Rowe Price Investment Management, Inc., among 54 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.